Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.435 USD | +1.06% | +2.14% | +6.72% |
Apr. 24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.72% | 358M | |
+30.29% | 662B | |
+21.96% | 546B | |
-5.28% | 359B | |
+16.69% | 323B | |
+4.70% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+4.14% | 167B |
- Stock Market
- Equities
- PGEN Stock
- News Precigen, Inc.
- JPMorgan Initiates Precigen at Neutral Rating